BioPharmSignal logoBioPharmSignal

Biotech News

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Hyperfine (HYPR)HyperfineFDA / regulatory

This newest software delivers improved image quality across Swoop system sequences, a more intuitive scanning experience, and new foundational isotropic imaging designed to strengthen the clinical utility of portable MRI. GUILFORD, Conn. --(BUSINESS WIRE)--Aug. 20, 2026-- Hyperfine, Inc.

Related news

HYPRHyperfine2026-07-30 12:15 EST

Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

VTAKCatheter Precision2026-09-02 20:15 EST

Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean

ICCMIceCure Medical2026-07-29 12:25 EST

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

ICUSeaStar Medical2026-10-07 12:16 EST

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

XAIRBeyond Air2026-08-31 12:00 EST

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

FEMYFEMASYS2026-08-19 13:00 EST

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

View all latest news

Hyperfine

Portable Brain MRI Company Hyperfine develops the Swoop portable magnetic resonance brain-imaging system for use at the patient’s bedside and in settings without conventional MRI infrastructure. Low-Field Imaging Platform Swoop uses low-field magnetic resonance and can be moved through hospitals, reducing the logistical burden of...

Recent company news

HYPRHyperfine2026-09-28 12:15 EST

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

HYPRHyperfine2026-08-31 12:15 EST

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

HYPRHyperfine2026-08-26 12:15 EST

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

HYPRHyperfine2026-08-20 12:15 EST

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Stock data

Close
0.87 USD
Market cap
148.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States